AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that it has entered a Research Collaboration and Option Agreement with Bristol Myers Squibb (NYSE: BMY) to discover and develop novel miniprotein-based therapeutics utilizing AI Proteins’ powerful discovery platform.

AI Proteins, Inc. 是一家利用计算从头蛋白质设计来创建治疗性微蛋白质的生物技术公司，今天宣布已与百时美施贵宝 (NYSE: BMY) 达成研究合作和选择协议，以利用 AI Proteins 强大的发现平台发现和开发基于微蛋白质的新型疗法。

Under this collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize miniproteins against targets of interest to Bristol Myers Squibb. These de novo designed miniproteins, characterized by their small size and high affinity, have the potential to offer significant advantages over traditional antibody-based therapies, including improved tissue penetration and rapid clearance.

根据此次合作，AI Proteins 将利用其专有的 AI 驱动平台来设计和优化针对百时美施贵宝感兴趣的靶点的微型蛋白。这些从头设计的微型蛋白具有体积小、亲和力高的特点，与传统的抗体疗法相比，具有显著的优势，包括更好的组织渗透性和快速清除率。

“We are excited to partner with Bristol Myers Squibb to bring our cutting-edge protein design technology to the clinic,” said Chris Bahl, PhD, President, CSO and Founder of AI Proteins. “Our platform combines AI, synthetic biology, and laboratory automation to rapidly design and optimize novel miniproteins with ideal drug-like properties. By combining our expertise in protein engineering with Bristol Myers Squibb’s deep knowledge of pharmaceutical development, we aim to create a new generation of targeted therapies that can transform patient outcomes.”

AI Proteins 总裁、首席科学官兼创始人 Chris Bahl 博士表示：“我们很高兴与百时美施贵宝合作，将我们尖端的蛋白质设计技术带入临床。我们的平台结合了人工智能、合成生物学和实验室自动化，可以快速设计和优化具有理想类药特性的新型微蛋白。通过将我们在蛋白质工程方面的专业知识与百时美施贵宝在药物开发方面的深厚知识相结合，我们旨在创造新一代靶向疗法，从而改变患者的治疗结果。”

Under the terms of the agreement, AI Proteins will receive an upfront cash payment for the collaboration under which the company will discover and optimize miniproteins for two undisclosed targets. Bristol Myers Squibb has an option for an exclusive worldwide license to these miniproteins as well as two additional target options in exchange for an expansion fee and potential development, regulatory, and commercial milestone payments valued up to $400M plus royalties on net sales.

根据协议条款，AI Proteins 将获得一笔预付现金，用于合作，该公司将根据该合作发现并优化两个未公开目标的微型蛋白。百时美施贵宝有权获得这些微型蛋白的全球独家许可以及两个额外的目标选项，以换取扩张费和潜在的开发、监管和商业里程碑付款，价值高达 4 亿美元，外加净销售额的特许权使用费。

About AI Proteins

关于AI Proteins

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo miniproteins optimized for a variety of therapeutic applications, and the company is currently advancing its own pipeline in oncology while exploring partnerships in inflammation, metabolic diseases and other therapeutic areas. The company’s technology enables the development of inexpensive, durable, highly specific proteins with unique therapeutic properties and with the potential for multiple routes of delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.

总部位于波士顿的 AI Proteins 是一家生物技术公司，其使命是通过一种设计全新蛋白质的新方法重新构想蛋白质疗法。AI Proteins 使用基于 AI 的设计和高通量药物发现平台，创建针对各种治疗应用优化的从头微型蛋白质，该公司目前正在推进其在肿瘤学领域的研发，同时探索在炎症、代谢疾病和其他治疗领域的合作。该公司的技术支持开发具有独特治疗特性并具有多种给药途径潜力的廉价、耐用、高度特异性的蛋白质。此外，AI Proteins 平台可以大大加速为 IND 支持研究做好准备的领先治疗候选物的开发。